Tri Locum Partners LP: MADRIGAL PHARMACEUTICALS INC (MDGL): Quarterly 13F Position History
As of Q1 2026, Tri Locum Partners LP reported 103,288 shares of MADRIGAL PHARMACEUTICALS INC (MDGL), worth $54.1M and representing 7.6% of its 13F equity book. Quarter-over-quarter share count change: + 17,265 (+20.1%) . The position first appeared in Q4 2022 and has been disclosed across 14 13F-HR filings in Pactolio's tracked window.
- 103,288Shares Held (Latest Filing)
- $54.1MReported Market Value (Latest Filing)
- 7.6%Portfolio Weight (% of 13F Equity Book)
- +17,265Quarter-over-Quarter Share Change
- +$4.0MQuarter-over-Quarter Value Change
- 103,288Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 14 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 103,288 | +17,265 | +20.1% | $54.1M | 7.6% | $523.5 |
| Q4 2025 | 86,023 | +18,317 | +27.1% | $50.1M | 6.5% | $582.3 |
| Q3 2025 | 67,706 | 30,059 | -30.7% | $31.1M | 7.1% | $458.7 |
| Q2 2025 | 97,765 | +59,896 | +158.2% | $29.6M | 9.0% | $302.6 |
| Q1 2025 | 37,869 | 9,603 | -20.2% | $12.5M | 6.4% | $331.2 |
| Q4 2024 | 47,472 | +4,185 | +9.7% | $14.6M | 3.0% | $308.6 |
| Q3 2024 | 43,287 | 22,065 | -33.8% | $9.2M | 2.2% | $212.2 |
| Q2 2024 | 65,352 | +11,997 | +22.5% | $18.3M | 4.6% | $280.2 |
| Q1 2024 | 53,355 | +27,831 | +109.0% | $14.2M | 4.9% | $267.0 |
| Q4 2023 | 25,524 | 8,237 | -24.4% | $5.9M | 2.9% | $231.4 |
| Q3 2023 | 33,761 | +7,751 | +29.8% | $4.9M | 1.6% | $146.0 |
| Q2 2023 | 26,010 | +12,165 | +87.9% | $6.0M | 2.2% | $231.0 |
| Q1 2023 | 13,845 | 12,541 | -47.5% | $3.4M | 1.0% | $242.3 |
| Q4 2022 | 26,386 | — | — | $7.7M | 3.4% | $290.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a MDGL position in 13F-HR filings?
Tri Locum Partners LP first reported MADRIGAL PHARMACEUTICALS INC (MDGL) on its 13F-HR filing for the period ending 2022-12-31 (Q4 2022). The position has appeared on 14 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in MDGL?
Between Q4 2025 and Q1 2026, Tri Locum Partners LP added 17,265 shares of MDGL (+20.1%), bringing the total reported position to 103,288 shares at a market value of $54.1M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in MDGL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.